For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.
Machaon Bonafede, PhD, MPH
Advertisement
Articles by Machaon Bonafede, PhD, MPH
Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies.
Advertisement
Latest Updated Articles
- Etanercept and Ustekinumab Dosing for Psoriasis and Psoriatic Arthritis
Published: September 21st 2017 | Updated:
- Compliance and Cost of Biologic Therapies for Rheumatoid Arthritis
Published: September 21st 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Is Berberine Nature’s GLP-1?
2
Experts Highlight Key Sessions and Emerging Topics from The Menopause Society 2025 Annual Meeting
3
Glucodensity Analysis Enhances CGM Accuracy for Detecting Cystic Fibrosis–Related Diabetes
4
Incidence of VAIs in Patients With Chronic Kidney Disease on Dialysis Relatively Low
5
